Evaluation of automated serum des-gamma-carboxyprothrombin (DCP) assays for detecting hepatocellular carcinoma

Clinical Biochemistry

Volumn 44, Issue 17-18, 2011, Pages 1464-1468

  Choi, Jonghyeon ^a   Park, Yongjung ^a   Kim, Jeong Ho ^a   Kim, Hyon Suk ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Automated analyzer; Des carboxyprothrombin (DCP); Hepatocellular carcinoma (HCC); Protein induced by vitamin K absence or antagonist II (PIVKA II); Reference range

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN;

ACCURACY; ADULT; AGED; ARTICLE; AUTOANALYSIS; AUTOANALYZER; CANCER DIAGNOSIS; CONTROLLED STUDY; DECARBOXYPROTHROMBIN BLOOD LEVEL; DILUTION; EVALUATION; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STANDARD;

ADULT; AGED; AUTOMATION, LABORATORY; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOASSAY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEIN PRECURSORS; PROTHROMBIN; QUALITY CONTROL; REFERENCE STANDARDS; REFERENCE VALUES; ROC CURVE;

EID: 81555219222     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.08.1144     Document Type: Article

References (31)

1. Shah D.V., Swanson J.C., Suttie J.W. Abnormal prothrombin in the vitamin K-deficient rat. Thromb Res 1984, 35(4):451-458.
2. Friedman P.A., Przysiecki C.T. Vitamin K-dependent carboxylation. Int J Biochem 1987, 19(1):1-7.
3. Huisse M.G., Leclercq M., Belghiti J., Flejou J.F., Suttie J.W., Bezeaud A., et al. Mechanism of the abnormal vitamin K-dependent gamma-carboxylation process in human hepatocellular carcinomas. Cancer 1994, 74(5):1533-1541.
4. Furie B., Furie B.C. Molecular basis of vitamin K-dependent gamma-carboxylation. Blood 1990, 75(9):1753-1762.
5. Kanazumi N., Takeda S., Inoue S., Ohshima K., Sugimoto H., Kaneko T., et al. PIVKA-II during perioperative period in patients with hepato-biliary-pancreatic diseases. Hepatogastroenterology 2000, 47(36):1695-1699.
6. Kasahara A., Hayashi N., Fusamoto H., Kawada Y., Imai Y., Yamamoto H., et al. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1993, 38(12):2170-2176.
7. Suehiro T., Matsumata T., Itasaka H., Taketomi A., Yamamoto K., Sugimachi K. Des-gamma-carboxy prothrombin and proliferative activity of hepatocellular carcinoma. Surgery 1995, 117(6):682-691.
8. Grazi G.L., Mazziotti A., Legnani C., Jovine E., Miniero R., Gallucci A., et al. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transpl Surg 1995, 1(4):249-255.
9. Liebman H.A., Furie B.C., Tong M.J., Blanchard R.A., Lo K.J., Lee S.D., et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984, 310(22):1427-1431.
10. Wang C.S., Lin C.L., Lee H.C., Chen K.Y., Chiang M.F., Chen H.S., et al. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma. World J Gastroenterol 2005, 11(39):6115-6119.
11. Kim D.Y., Paik Y.H., Ahn S.H., Youn Y.J., Choi J.W., Kim J.K., et al. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology 2007, 72(Suppl 1):52-57.
12. Morota K., Nakagawa M., Sekiya R., Hemken P.M., Sokoll L.J., Elliott D., et al. A comparative evaluation of Golgi protein-73, fucosylated hemopexin, alpha-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Clin Chem Lab Med 2011, 49(4):711-718.
13. Shimada M., Yamashita Y., Hamatsu T., Hasegawa H., Utsunomiya T., Aishima S., et al. The role of des-gamma-carboxy prothrombin levels in hepatocellular carcinoma and liver tissues. Cancer Lett 2000, 159(1):87-94.
14. Inoue S., Nakao A., Harada A., Nonami T., Takagi H. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma. Am J Gastroenterol 1994, 89(12):2222-2226.
15. Tamano M., Sugaya H., Oguma M., Iijima M., Yoneda M., Murohisa T., et al. Serum and tissue PIVKA-II expression reflect the biological malignant potential of small hepatocellular carcinoma. Hepatol Res 2002, 22(4):261-269.
16. Toyoda H., Kumada T., Kiriyama S., Sone Y., Tanikawa M., Hisanaga Y., et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006, 4(1):111-117.
17. Inagaki Y., Tang W., Makuuchi M., Hasegawa K., Sugawara Y., Kokudo N. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-gamma-carboxyprothrombin. Liver Int 2011, 31(1):22-35.
18. Tateishi R., Yoshida H., Matsuyama Y., Mine N., Kondo Y., Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int 2008, 2(1):17-30.
19. Nomura F., Ishijima M., Kuwa K., Tanaka N., Nakai T., Ohnishi K. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 1999, 94(3):650-654.
20. Sassa T., Kumada T., Nakano S., Uematsu T. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma. Eur J Gastroenterol Hepatol 1999, 11(12):1387-1392.
21. Kawabata T., Watanabe M., Nakamura K., Satomura S. Liquid-phase binding assay of alpha-fetoprotein using DNA-coupled antibody and capillary chip electrophoresis. Anal Chem 2005, 77(17):5579-5582.
22. Kagebayashi C., Yamaguchi I., Akinaga A., Kitano H., Yokoyama K., Satomura M., et al. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal Biochem 2009, 388(2):306-311.
23. Sugimoto H., Takeda S., Inoue S., Kaneko T., Watanabe K., Nakao A. Des-gamma-carboxy prothrombin (DCP) ratio, a novel parameter measured by monoclonal antibodies MU-3 and 19B7, as a new prognostic indicator for hepatocellular carcinoma. Liver Int 2003, 23(1):38-44.
24. Marrero J.A., Su G.L., Wei W., Emick D., Conjeevaram H.S., Fontana R.J., et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003, 37(5):1114-1121.
25. Pesce M.A. Laboratory automation. Clinical Chemistry 2003, 294. Mosby, Baltimore. 4 ed. L.A. Kaplan, A.J. Pesce (Eds.).
26. Sherman M., Peltekian K.M., Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995, 22(2):432-438.
27. Di Bisceglie A.M., Hoofnagle J.H. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer 1989, 64(10):2117-2120.
28. Tsai S.L., Huang G.T., Yang P.M., Sheu J.C., Sung J.L., Chen D.S. Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma. Hepatology 1990, 11(3):481-488.
29. Colombo M., de Franchis R., Del Ninno E., Sangiovanni A., De Fazio C., Tommasini M., et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991, 325(10):675-680.
30. Pateron D., Ganne N., Trinchet J.C., Aurousseau M.H., Mal F., Meicler C., et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994, 20(1):65-71.
31. Kishi K., Sonomura T., Mitsuzane K., Nishida N., Kimura M., Satoh M., et al. Time courses of PIVKA-II and AFP levels after hepatic artery embolization and hepatic artery infusion against hepatocellular carcinoma: relation between the time course and tumor necrosis. Radiat Med 1992, 10(5):189-195.